The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.

Overview

Main objective : To develop the tools for evaluation of humoral and cell-mediated immunity after Yellow Fever Vaccine (YFV) and compare virological and immune responses in HIV-positive and HIV-negative individuals who had not been given YFV before. Secondary objectives : – To develop and assess ELISPOT technology for yellow fever and to measure the response within 7, 14, 28, 90 and 365 days of administration of YFV in 30 HIV negative subjects and 40 HIV positive subjects (CD4 > 350/mm3 under Highly Active Antiretroviral Therapy (HAART) for at least one year, with a viral load < 50 copies/mL since at least 6 months) in terms of : (1) seroconversion by fluorescence, (2) cytotoxic response in ELISPOT, (3) neutralizing antibody levels in Plaque reduction neutralization test (PRNT:reference method) and a new pseudotype based method, (4) post-vaccination viremia and (5) diversity of viral quasi-species. – To assess the impact of YFV on the T-lymphocyte response against HIV by ELISPOT and viral load.

Full Title of Study: “The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2017

Detailed Description

Method : Clinical Trial Phase III, Multicentre protocol at Saint-Louis hospital, Bichat hospital and Cochin-Pasteur hospital, with CERVI, INSERM U 941 and SC10 collaboration. Trial treatment : Yellow fever vaccination (STAMARIL) Criterion : Immuno-virologic: At J-7, J7, J28, M3 and M12 will be determined the levels of antibodies by fluorescence, at J0, J7, J28, M3 and M12 titles and neutralization with Prnt pseudotypes, the ELISPOT response anti-yellow fever, viremia with quantitative analysis and nucleotide sequences on phylogenetic strains of viremia. Titles and Amariles kinetics of viremia, neutralizing antibodies and ELISPOT will be considered as surrogate markers of response in terms of groups. Clinical and biological tolerance: At all follows up will be measured the incidence of CDC classification events (for HIV+) and general and local reactions of degree ≥ 2 in the setting of the injection of STAMARIL®. Schedule : Date of first enrolment : third quarter 2011. Inclusion period : 18 months. For each subject, participation in this trial will be for 12 months.

Interventions

  • Biological: Yellow fever vaccination (STAMARIL)
    • Yellow fever vaccination (STAMARIL)
  • Biological: Yellow fever vaccination (STAMARIL)
    • Yellow fever vaccination (STAMARIL)

Arms, Groups and Cohorts

  • Active Comparator: Voluntary HIV positive subjects
    • 40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
  • Other: HIV negative subjects
    • Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year

Clinical Trial Outcome Measures

Primary Measures

  • Immuno-virologic criterion
    • Time Frame: DAY-7
    • – At Day-7 will be determined the levels of antibodies by fluorescence.
  • Immuno-virologic criterion
    • Time Frame: Day 0
    • At Day 0 will be determined titles and neutralization with Prnt pseudotypes, the ELISPOT response anti-yellow fever, viremia with quantitative analysis and nucleotide sequences on phylogenetic strains of viremia
  • Immuno-virologic criterion
    • Time Frame: Day 28
    • At Day 28 will be determined titles and neutralization with Prnt pseudotypes, the ELISPOT response anti-yellow fever, viremia with quantitative analysis (if it’s positive at day7) and nucleotide sequences on phylogenetic strains of viremia
  • Immuno-virologic criterion
    • Time Frame: Month 3
    • At Month 3 will be determined fluorescence, PRNT and ELISPOT.
  • Immuno-virologic criterion
    • Time Frame: Month 12
    • At Month 12 will be determined fluorescence, PRNT and ELISPOT.
  • Immuno-virologic criterion
    • Time Frame: Day 7
    • At Day 7 will be determined titles and neutralization with Prnt pseudotypes, the ELISPOT response anti-yellow fever, viremia with quantitative analysis and nucleotide sequences on phylogenetic strains of viremia

Secondary Measures

  • Clinical and biological tolerance
    • Time Frame: day -7
    • At Day -7 will be determined the levels of antibodies by fluorescence
  • clinical and biological tolerance
    • Time Frame: day 0
    • At Day 0: incidence of HIV+ event and general+local reactions of d°>2 after vaccination
  • clinical and biological tolerance
    • Time Frame: day 7
    • At Day7: incidence of HIV+ event and general+local reactions of d°>2 after vaccination
  • clinical and biological tolerance
    • Time Frame: day 14
    • At Day14:incidence of HIV+ event and general+local reactions of d°>2 after vaccination
  • clinical and biological tolerance
    • Time Frame: day 28
    • At Day 28:incidence of HIV+ event and general+local reactions of d°>2 after vaccination
  • clinical and biological tolerance
    • Time Frame: month 3
    • At Month3:incidence of HIV+ event and general+local reactions of d°>2 after vaccination
  • clinical and biological tolerance
    • Time Frame: month 12
    • At Month 12:incidence of HIV+ event and general+local reactions of d°>2 after vaccination

Participating in This Clinical Trial

Group 1: Voluntary HIV positive subjects Inclusion Criteria:

  • Adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment) – > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months. – Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen. Exclusion Criteria:

  • Previous vaccination against yellow fever or yellow fever Fluorescence anti-IgG positive. – Administration of immunoglobulins < 3 months or any vaccine <1 month. – Pregnancy ongoing or planned during the study. – Coinfection with HCV virus untreated. – HBs Ag positive. – Hypersensitivity reaction to eggs / chicken protein; hereditary fructose intolerance. – Immunosuppression, whether congenital, idiopathic or as a result of corticosteroids systemically (at doses ≥ 20mg/d of prednisone), or due to radiation or antineoplastic older than 6 months. – History of thymic dysfunction (including thymoma and thymectomy). – For HIV + subjects: ART Celsentri or by other anti-CCR5. Group 2: HIV negative subjects Inclusion Criteria:

HIV and HCV negatives Exclusion Criteria:

  • Previous vaccination against yellow fever or yellow fever Fluorescence anti-IgG positive. – Administration of immunoglobulins < 3 months or any vaccine <1 month. – Other vaccinations should be deferred beyond M3. – Pregnancy ongoing or planned during the study. – Coinfection with HCV virus untreated. – HBs Ag positive. – Hypersensitivity reaction to eggs / chicken protein; hereditary fructose intolerance. – Immunosuppression, whether congenital, idiopathic or as a result of corticosteroids systemically (at doses ≥ 20mg/d of prednisone), or due to radiation or antineoplastic older than 6 months. – History of thymic dysfunction (including thymoma and thymectomy). – For HIV + subjects: ART Celsentri or by other anti-CCR5, coinfection with HCV virus untreated

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • French National Agency for Research on AIDS and Viral Hepatitis
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nathalie COLIN de VERDIERE, Principal Investigator, Maladies Infectieuses St Louis Paris
    • Sophie MATHERON, Principal Investigator, Maladies Infectieuses et Tropicales Bichat Paris
    • Odile LAUNAY, Principal Investigator, CIC Cochin Paris

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.